A scanning electron microscope image showing SARS-CoV-2 (orange), the virus that causes COVID-19, isolated from a patient in the US, emerging from the surface of cells cultured in the lab. Photo and caption: NIAID-RML.
COVID-19 continues to be an immense global challenge, with over 5.2 million confirmed cases and over 338,000 deaths.
In this gloom, science offers hope. Never before have scientists come together to do so much in so little time. Important research that stayed behind paywalls earlier is now openly accessible; over 5,000 articles on preprint servers and over 30,000 viral genome sequences are freely available.
Vaccines against the SARS-CoV-2 virus are also being developed at pandemic speed with 10 candidates in clinical testing and another 114 in pre-clinical development. But the basic understanding of whether a vaccine would work, what might be the correlates of protection, and how would one measure those, has been lacking. This was addressed recently.
Most vaccines in development aim to produce antibodies that would disable the virus from entering target cells. These are produced by B cells. Another arm of immunity utilises T-cells that thwart infection in two ways the helper T-cells help B-cells produce antibodies, and the killer T-cells seek out and destroy virus-infected cells. But a small fraction of virus-specific B, helper-T and killer-T cells also develop into memory cells, which respond very quickly to future infections by the same pathogen.
The success of most COVID-19 vaccines under development rests on whether they can produce neutralising antibodies. How does one measure these antibodies? How long do these take to develop, and how long do they last?
Researchers from Emory University in Atlanta, USA provide answers to some of these questions in a preprint paper posted on the medRxiv server on May 8. Using molecular biology and biochemical tools they obtained purified receptor binding domain (RBD) of the spike protein, which contacts the ACE2 receptors on target cells to facilitate virus entry (see illustration). Antibodies to RBD are expected to neutralise the virus.
The RBD protein was used to develop blood tests to look for anti-RBD antibodies in COVID-19 patients and assess their ability to neutralise the virus in 44 patients. The study showed that RBD-specific and virus-neutralising antibodies correlated nicely and developed very early after SARS-CoV-2 infection. When validated with 231 hospitalised COVID-19 patients, the RBD-specific antibody test was highly sensitive and specific, and found to be a good surrogate for measuring neutralising antibodies.
These findings have important implications for our understanding of protective immunity against SARS-CoV-2, the use of immune plasma as a therapy, and the development of much-needed vaccines, said Mehul S. Suthar, co-lead author of the study, in an Emory University press release. This study provides a snapshot of the immune response as it is happening, not after the battle is over, he added.
Two recent papers looked at T-cells to SARS-CoV-2. In a paper published May 14, researchers at the La Jolla Institute for Immunology, California, designed peptides (small fragments) corresponding to various SARS-CoV-2 proteins and exposed blood cells from COVID-19 patients to these snippets. Their results showed that all patients carried helper T-cells and over 70% also carried killer T-cells, suggesting that the immune system was seeing the virus and mounting a response. These results agreed well with a study from Charit University Hospital, Berlin, posted on medRxiv on April 22.
These and many other T-cell studies are assisted by the Immune Epitope Database and Analysis Resource and the IEDB website, which is the bread and butter of T-cell epitope mapping.
But the real surprise came when blood cells from people who had no SARS-CoV-2 infection were exposed to these peptides. About a third in the Berlin study and about half in the La Jolla study carried the memory T-cells. These are likely to be from past exposure to one of four other human coronaviruses that are endemic and are estimated to cause 20-30% of common cold annually.
These are comprehensive studies characterising the T-cell response to COVID-19 virus, says Rafi Ahmed, a leading immunologist and director of the Vaccine Centre at Emory University, Atlanta. This information will be useful in designing vaccines that induce T cell immunity against COVID-19, adds Ahmed, who is also a fellow of the US National Academy of Sciences.
Most vaccines under development aim to produce an immune response against the viral spike protein, but the La Jolla study showed the presence of T cells that recognise several other viral proteins. As Ahmed suggests, these studies inform vaccine design by recommending the inclusion of other proteins as well. The whole virus attenuated and killed vaccines may therefore offer better and longer lasting protection compared to single protein vaccines.
Though T-cells are often overlooked and neutralising antibodies are typically considered a correlate to protection, it is well established that poor T cells result in poor memory B-cells and thus long-lived antibodies something all vaccine manufactures and proponents of herd immunity are looking for, says Anmol Chandele, group leader of the ICGEB-Emory Vaccine Programme at the International Centre for Genetic Engineering and Biotechnology, New Delhi.
The blood test developed at Emory University also helps inform vaccine development. Scientists could test the blood of vaccine study participants for the RBD-specific antibodies as a measure of neutralising antibodies, and use it predict vaccine efficacy. The infusion of blood plasma from recovered COVID-19 patients has been proposed as a potential therapy for critical patients. This blood test would also be useful in assessing the therapeutic value of convalescent plasma before infusion.
The Emory University researchers are now using the blood test to assess neutralising antibodies in people who get mild disease or remain asymptomatic. This would inform if such people are at a risk of re-infection. In a pandemic situation, it may also be better placed to offer immunity passports.
Commenting on the Emory study, of which he is an author, Ahmed says, This study makes the important observation that COVID-19 patients rapidly generate neutralising antibodies against the virus. This is a very hopeful sign for protective immunity against re-infection in the recovered patients. This, he says has important implications for public health and for COVID-19 vaccines.
The La Jolla T-cell study links well with the Emory antibody study, where the key result is that RBD-binding antibody titres beautifully correlate to neutralising antibody titres in an individual, adds Chandele, who was not part of either study.
These studies offer hope that vaccine developers will no longer fly blind.
Dr Shahid Jameel is a former Group Leader of Virology at ICGEB, New Dehi, India. He is currently CEO, DBT/Wellcome Trust India Alliance.
Read the original post:
COVID-19 Vaccines: A Reason to Hope We're Flying Blind No More - The Wire
- Lords seek to allow gene-editing in UK 'to produce healthy, hardier crops' - The Guardian - June 20th, 2020
- Ginkgo Bioworks CEO on scaling up Covid-19 testing: 'If we try, we can win' - CNBC - June 20th, 2020
- GlobalGenome Engineering Market Report 2020 Sales Forecast to Grow Negatively in Western Regio post COVID 19 Impact Analysis Updated Edition Top... - June 20th, 2020
- Coronavirus vaccines are coming, but when will they arrive? - Digital Journal - June 20th, 2020
- Swiss men aspire to live to 108.5 years old - MENAFN.COM - June 20th, 2020
- Bioengineered Protein Drugs Market Professional Survey 2020 by Manufacturers, Share, Growth, Trends, Types and Applications, Forecast to 2026 -... - June 20th, 2020
- Texas A&M Researcher Creating Better Corn Yields, Quality On Less Land - Texas A&M University Today - June 20th, 2020
- Annecy Pitches: 5 Film Projects That Caught Our Eye - Cartoon Brew - June 20th, 2020
- Italy and Israel bet on GM microalgae to develop edible COVID vaccine - Alliance for Science - June 13th, 2020
- GM seeds: the debate, and a sowing agitation - The Indian Express - June 13th, 2020
- Viral Vector and Plasmid DNA Testing Services Market Players focusing on the invention of new techniques in a bid to better the characterization of... - June 13th, 2020
- What scientists are learning about COVID-19 from animals - WISHTV.com - June 13th, 2020
- How Receptive are Consumers to Agricultural Biotech? - Food Institute Focus - Food Institute Blog - June 13th, 2020
- Egg-based coating preserves fresh produce - Feedstuffs - June 13th, 2020
- Fat alternative Epogee gains traction: 'The low-fat ship sailed 25 years ago, this is not about low fat, it's about caloric reduction' -... - June 13th, 2020
- CRISPR-Based Therapeutics Market with Report In Depth Industry Analysis on Trends, Growth, Opportunities and Forecast - Cole of Duty - June 13th, 2020
- Gene Therapy and Editing : Novel options for inherited retinal blindness - ETHealthworld.com - June 13th, 2020
- Fat cells remember their diets early in life - Massive Science - June 13th, 2020
- Researchers find new selective-breeding method for heat-tolerant abalone without genetic modification - Aju Business Daily - May 29th, 2020
- Ethicists: We need more flexible tools for evaluating gene-edited food - The Conversation US - May 29th, 2020
- On the Origins of Modern Biology and the Fantastic: Part 18 Nalo Hopkinson and Stem Cell Research - tor.com - May 29th, 2020
- global market for viral vector and plasmid manufacturing is predicted to grow at a CAGR of 16.28% over the forecast period of 2020-2030 - Salamanca... - May 29th, 2020
- COVID-19: Responding to the business impacts of CRISPR And CRISPR-Associated (Cas) Genes Market 2019 Trends, Size, Segments, Emerging Technologies and... - May 29th, 2020
- Astronauts can change DNA for the colonization of Mars - The Times Hub - May 29th, 2020
- Potential impact of coronavirus outbreak on Zinc Finger Nuclease Technology Market: Opportunities and Forecast Assessment, 2019-2027 - Jewish Life... - May 29th, 2020
- Genes linked to evolution of languages - Cosmos - May 29th, 2020
- Global Food Enzymes Market (2020 to 2025) - Recent Innovations in the Market - GlobeNewswire - May 29th, 2020
- The impact of the coronavirus on the Genetic Engineering Market Solid Analyzed Segmentation, Demand, Recent Share Estimation and Growth Prospects by... - May 24th, 2020
- One of the World's Most Powerful Scientists Believes in Miracles - Scientific American - May 24th, 2020
- Emerging from stealth, Octant is bringing the tools of synthetic biology to large scale drug discovery - TechCrunch - May 24th, 2020
- Humans will be able to replace their bodies within 50 years claims transhumanist writer - Express.co.uk - May 24th, 2020
- Menu of solutions, no silver bullet, to feed the world - FeedStrategy.com - May 24th, 2020
- Emerging courses: How to become a healthcare engineer - The Indian Express - May 24th, 2020
- Why Italians aren't all the same - Cosmos - May 24th, 2020
- Coronavirus: Parliament told there is 'no evidence' virus came from Wuhan laboratory - Sky News - May 24th, 2020
- Yeast fermentation may be the answer to creating rare cannabinoids - Leafly - May 24th, 2020
- Climate change and coronavirus: Is the Covid-19 pandemic really a surprise? - DailyO - May 24th, 2020
- Dyno Debuts With Plan, Partnerships For Better Gene Therapy Vectors - Xconomy - May 11th, 2020
- Your genes could determine whether the coronavirus puts you in the hospital and we're starting to unravel which ones matter - The Conversation US - May 11th, 2020
- How Covid-19 Can Save the World's Bee Population - CTech - May 11th, 2020
- B-P names Top 10 students in Class of 2020 - The Recorder - May 11th, 2020
- Whether the Coronavirus Puts You in the Hospital Could Depend on Your Genes And Were Unraveling Which Ones Matter - SciTechDaily - May 11th, 2020
- Biotech and Investment Veteran Dennis Purcell Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.... - May 11th, 2020
- Researchers Develop New Classification Tool to Find COVID-19 Genetic Signature - ENGINEERING.com - May 11th, 2020
- Covid-19: What you need to know today - Hindustan Times - May 11th, 2020
- Exercise may help reduce the risk of deadly COVID-19 complication - GOOD Magazine - May 11th, 2020
- Scientists Find New Way to Inject Plants With Medicine, And It May Help Save Our Crops - ScienceAlert - May 4th, 2020
- This Week's Awesome Tech Stories From Around the Web (Through May 2) - Singularity Hub - May 4th, 2020
- The Pandemic and America's Response to Future Bioweapons - War on the Rocks - May 4th, 2020
- Blue-sky thinking for food production - Farm Weekly - May 4th, 2020
- The pieces of the puzzle of covid-19s origin are coming to light - The Economist - May 4th, 2020
- Merck & Co. Partnering with ISB to Study Targets for COVID-19 Therapeutics - Genetic Engineering & Biotechnology News - May 4th, 2020
- The next pandemic could be even worse - CNN - May 4th, 2020
- We need more honesty in GMO discussions - Ethiopia Observer - May 4th, 2020
- Covid-19 treatment on the horizon but vaccine remains elusive - Pharmaceutical Technology - May 4th, 2020
- Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies -... - May 4th, 2020
- Better Predicting the Unpredictable Byproducts of Genetic Modification - NC State News - April 11th, 2020
- Fiction about pandemics and dystopian future - Dhaka Tribune - April 11th, 2020
- David Lynch believes the world will be a more spiritual, much kinder place after lockdown ends - Far Out Magazine - April 11th, 2020
- Tension Builds Over Drug To Treat COVID-19 - caribbeannationalweekly.com - April 11th, 2020
- Disease is the greatest threat to bee health. Can we protect them through genetically engineered probiotics? - Genetic Literacy Project - April 9th, 2020
- CSL Behring and SAB Biotherapeutics Join Forces to Deliver New Potential COVID-19 Therapeutic - P&T Community - April 9th, 2020
- CAR T-Cell Therapy for Multiple Myeloma - Global Market Insights and Market Forecast to 2030 - ResearchAndMarkets.com - Yahoo Finance - April 9th, 2020
- One in four Britons 'think the coronavirus was probably created in a lab' - Yahoo Sports - April 9th, 2020
- Fear of global plagues and greed for money are as old as mankind - SowetanLIVE - April 9th, 2020
- CRISPR gene editing could yield drought-tolerant tomatoes and kiwis that grow in salty soil - Genetic Literacy Project - March 31st, 2020
- How the novel coronavirus is mutating, and if you should be concerned - ThePrint - March 31st, 2020
- India What we know about the genome of the virus in India A mutation unique to - Times of India - March 31st, 2020
- Why can't we have a COVID-19 vaccine right now? - OnCubaNews - March 31st, 2020
- Column: Roswell Park's alliance with Cuba gets the 'wow' treatment from PBS' 'Nova' - Buffalo News - March 31st, 2020
- Scientist says anti-epilepsy drug can be repurposed for Covid-19, writes to ICMR to test it - ThePrint - March 31st, 2020
- Treatment gets five out of Intensive Care - Dominican Today - March 31st, 2020
- Cannabis Compound CBD Acts as Helper to Boost Antibiotic Effectiveness - Genetic Engineering & Biotechnology News - March 31st, 2020
- A Bioweapon Or Effects Of 5G? 7 Conspiracy Theories Around Coronavirus That Will Shock You - The Biggest Humanitarian Crisis - Economic Times - March 31st, 2020
- Is the Indian COVID-19 strain weaker? - Times of India - March 26th, 2020
- Timeline Shows 3 Paths To COVID-19 Treatment And Prevention (INFOGRAPHIC) - Forbes - March 26th, 2020
- This Fulbright scholar wants to find ways to prevent or slow the spread of cancer - News@Northeastern - March 26th, 2020
- Covid 19: HOMEF Cautions On Use of Biodiversity - Leadership Newspaper - March 26th, 2020
- Genetically targeted chemical assembly of functional materials in living cells, tissues, and animals - Science Magazine - March 25th, 2020
- What Anti-Science Activists And Lawyers Have In Common During This Crisis They Share The Rest Of The Time: Fear Profiteering - Science 2.0 - March 25th, 2020